Annotation Detail

Information

Associated Genes: BRAF
Associated Variants: BRAF p.Val640Glu (p.V640E) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 )
BRAF p.Val640Glu (p.V640E) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 )
Associated Disease: colorectal cancer
Source Database: CIViC Evidence
Description: Phase 1b study of vemurafenib, cetuximab and irinotecan in 19 patients with colorectal cancer (1 with appendiceal cancer). Six of 17 evaluable patients achieved an objective response, 15 patients total had either stable disease or radiographic response (the patient with appendiceal cancer had disease progression). Estimated median PFS was 7.7 months. Effect of the combined treatment was also observed in xenograft and cell line studies.
Variant Origin: somatic
Variant Origin: Somatic
Evidence URL: https://civic.genome.wustl.edu/links/evidence_items/1902
Gene URL: https://civic.genome.wustl.edu/links/genes/5
Variant URL: https://civic.genome.wustl.edu/links/variants/12
Rating: 4
Evidence Type: Predictive
Disease: Colorectal Cancer
Evidence Direction: Supports
Drug: Irinotecan,Cetuximab,Vemurafenib
Evidence Level: B
Clinical Significance: Sensitivity/Response
Pubmed: 27729313

Drugs